Castleview Partners, LLC: XJQCX position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Castleview Partners, LLC on XJQCX, newest first. How the timeline and the estimate are built.
Castleview Partners, LLC held 168,987 XJQCX shares at 2026-09-30 per its 13F-HR filed 2026-10-09.
the latest 13F is the newest step
- period ended2026-09-3013F 168,987 sharesChange vs previous 13F +13,279 shares
0.35% of the 13F portfolio, value $802,688.
13F-HR 0001737088-26-000009 filed by Castleview Partners, LLC
Accepted , ingested - period ended2026-06-3013F 155,708 sharesChange vs previous 13F +4,470 shares
0.33% of the 13F portfolio, value $756,745.
13F-HR 0001737088-26-000007 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2026-03-3113F 151,238 sharesChange vs previous 13F -261,178 shares
0.38% of the 13F portfolio, value $736,529.
13F-HR 0001737088-26-000004 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F 412,416 sharesChange vs previous 13F +189,677 shares
1.03% of the 13F portfolio, value $2,070,328.
13F-HR 0001737088-26-000003 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-09-3013F 222,739 sharesChange vs previous 13F +6,652 shares
0.64% of the 13F portfolio, value $1,173,835.
13F-HR 0001737088-25-000008 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 216,087 sharesChange vs previous 13F not available
0.75% of the 13F portfolio, value $1,164,709.
13F-HR 0001737088-25-000006 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).